Market›Motexafin lutetium
Company Profile

Motexafin lutetium

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

Clinical trials
Phase II clinical trials were in progress in 1999. A phase I trial for prostate cancer reported in 2009. ==References==
Source: Wikipedia ↗
tickerdossier.comtickerdossier.substack.com